Cost-Effectiveness Analysis of Nilotinib Versus High-Dose Imatinib for the Second-Line Treatment of Chronic Myeloid Leukemia In China - Based on Nation-Wide Data

May 1, 2018, 00:00 AM
10.1016/j.jval.2018.04.1712
https://www.valueinhealthjournal.com/article/S1098-3015(18)32034-5/fulltext
Section Title :
Section Order : 938
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)32034-5&doi=10.1016/j.jval.2018.04.1712
HEOR Topics :
Tags :
Regions :